



Dkt. 43016-A-PCT-US/JPW/CY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154 Examiner: A. Holleran  
Filed : November 16, 1995 Group Art Unit: 1642  
For : GANGLIOSIDE-KLH CONJUGATE VACCINES WITH QS-21

1185 Avenue of the Americas  
New York, New York 10036

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SIR:

TERMINAL DISCLAIMER

Sloan-Kettering Institute for Cancer Research, 1275 York Avenue, New York, New York 10021 ("Sloan-Kettering") is the Assignee of record of the entire right, title and interest in and to this application by virtue of an Assignment from Philip O. Livingston and Friedhelm Helling to Sloan-Kettering which was recorded in the U.S. Patent and Trademark Office on January 21, 1994 at Reel No. 014168, Frames 0952-0955, a copy of which is attached hereto as **EXHIBIT 1**, in connection with PCT International Application No. PCT/US94/00757. The present application, U.S. Serial No. 08/196,154, is the §37.1 national stage of PCT International Application No. PCT/US94/00757.

Sloan-Kettering is also the Assignee of record of the entire right, title and interest in and to U.S. Serial No. 08/477,097, filed June 7, 1995, by virtue of an Assignment from Philip O. Livingston and Friedhelm Helling to Sloan-Kettering which was recorded in the U.S. Patent and Trademark Office on November 9, 1995, at Reel No. 7707, Frames 0968-0971, a copy of which is attached hereto as **EXHIBIT 2**.

06/20/2005 KODAK T00000001 033125154  
01 FC:2014 65.00 DA

BEST AVAILABLE COPY

Applicants: Philip O. Livingston and Friedhelm Helling  
Serial No.: 08/196,154  
Filed : November 16, 1995  
Page 4

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date: 3/8/05

Sloan-Kettering Institute  
for Cancer Research

By:

James S. Quirk  
James S. Quirk  
Senior Vice-President,  
Research Resources Management  
Sloan-Kettering Institute  
for Cancer Research